Skip to main content
Top
Published in: Lung 4/2018

01-08-2018 | INTERSTITIAL LUNG DISEASE

Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management

Authors: Gabriela Leuschner, Fredrik Reiter, Florian Stocker, Alexander Crispin, Nikolaus Kneidinger, Tobias Veit, Friederike Klenner, Felix Ceelen, Gregor Zimmermann, Hanno Leuchte, Simone Reu, Julien Dinkel, Jürgen Behr, Claus Neurohr

Published in: Lung | Issue 4/2018

Login to get access

Abstract

Introduction

Idiopathic pulmonary fibrosis (IPF) is considered a disease of older patients, being rare in patients ≤ 50 years. Still, IPF can occur in younger patients, but this particular patient group is not well characterised so far. The aim of this study was to compare the diagnostic certainty, clinical features, comorbidities and survival in young versus older IPF patients.

Methods

We reviewed our medical records from February 2011 until February 2015, to identify IPF patients, who were then classified as young (≤ 50 years) or older IPF (> 50 years). Radiographic and histological findings, lung function parameters, comorbidities, disease progression and survival were analysed and compared between the two groups.

Results

Of 440 patients with interstitial lung disease, 129 patients with IPF were identified, including 30 (23.3%) ≤50 years and 99 (76.7%) > 50 years. There were no differences between age groups in baseline demographics; younger patients were less likely to have a confirmed diagnosis by high-resolution computed tomography (p = 0.014), more likely to require a biopsy (p = 0.08) and less likely to have received antifibrotic therapy (p = 0.006). Despite an overall limited prognosis, younger patients had a significantly better median survival after diagnosis (p = 0.0375), with a significantly higher proportion of older patients dying due to respiratory failure (p = 0.0383).

Conclusion

IPF patients under the age of 50 years have similar features and clinical course compared to older IPF patients. These patients should be diagnosed by adopting a multidisciplinary team approach, potentially benefitting from earlier intervention with effective antifibrotic therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedPubMedCentral
2.
go back to reference Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140:221–229CrossRefPubMed Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140:221–229CrossRefPubMed
3.
go back to reference Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985CrossRefPubMedPubMedCentral Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985CrossRefPubMedPubMedCentral
4.
go back to reference Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Glaser S, Gottlieb J et al (2013) [German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie 67:81–111CrossRefPubMed Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Glaser S, Gottlieb J et al (2013) [German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie 67:81–111CrossRefPubMed
5.
go back to reference Nadrous HF, Myers JL, Decker PA, Ryu JH (2005) Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 80:37–40CrossRefPubMed Nadrous HF, Myers JL, Decker PA, Ryu JH (2005) Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 80:37–40CrossRefPubMed
6.
go back to reference Neurohr C, Behr J (2015) Changes in the current classification of IIP: a critical review. Respirology 20:699–704CrossRefPubMed Neurohr C, Behr J (2015) Changes in the current classification of IIP: a critical review. Respirology 20:699–704CrossRefPubMed
7.
go back to reference Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRefPubMed Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRefPubMed
8.
go back to reference McEvoy JD, Jones NL (1975) Arterialized capillary blood gases in exercise studies. Med Sci Sports 7:312–315PubMed McEvoy JD, Jones NL (1975) Arterialized capillary blood gases in exercise studies. Med Sci Sports 7:312–315PubMed
9.
go back to reference Laboratories, ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef Laboratories, ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef
10.
go back to reference Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691CrossRefPubMed Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691CrossRefPubMed
11.
go back to reference Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:D42-50CrossRefPubMed Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:D42-50CrossRefPubMed
12.
go back to reference Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J (2004) Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43:764–770CrossRefPubMed Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J (2004) Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43:764–770CrossRefPubMed
13.
go back to reference Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C (2014) Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 19:700–706CrossRefPubMed Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C (2014) Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 19:700–706CrossRefPubMed
14.
go back to reference Moua T, Maldonado F, Decker PA, Daniels CE, Ryu JH (2014) Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc 89:319–326CrossRefPubMed Moua T, Maldonado F, Decker PA, Daniels CE, Ryu JH (2014) Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc 89:319–326CrossRefPubMed
15.
go back to reference Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ (2016) Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE 11:e0151425CrossRefPubMedPubMedCentral Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ (2016) Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE 11:e0151425CrossRefPubMedPubMedCentral
16.
go back to reference Raghu G, Amatto VC, Behr J, Stowasser S (2015) Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46:1113–1130CrossRefPubMed Raghu G, Amatto VC, Behr J, Stowasser S (2015) Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46:1113–1130CrossRefPubMed
17.
go back to reference King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171–1181CrossRefPubMed King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171–1181CrossRefPubMed
18.
go back to reference Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167:962–969CrossRefPubMed Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167:962–969CrossRefPubMed
19.
go back to reference Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, Koth LL (2017) Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest 152(3):502–509CrossRefPubMed Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, Koth LL (2017) Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest 152(3):502–509CrossRefPubMed
20.
go back to reference Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V et al (2016) Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47:1767–1775CrossRefPubMedPubMedCentral Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V et al (2016) Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47:1767–1775CrossRefPubMedPubMedCentral
21.
go back to reference Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816CrossRefPubMed Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816CrossRefPubMed
22.
Metadata
Title
Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management
Authors
Gabriela Leuschner
Fredrik Reiter
Florian Stocker
Alexander Crispin
Nikolaus Kneidinger
Tobias Veit
Friederike Klenner
Felix Ceelen
Gregor Zimmermann
Hanno Leuchte
Simone Reu
Julien Dinkel
Jürgen Behr
Claus Neurohr
Publication date
01-08-2018
Publisher
Springer US
Published in
Lung / Issue 4/2018
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-018-0123-9

Other articles of this Issue 4/2018

Lung 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.